Too many patient access strategies stop at “script filled”. But this approach is ultimately short-sighted, failing to build ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

The Trump administration has extended the duration of a pilot programme to provide access to obesity drugs through Medicare, ...

In the pharmaceutical and healthcare sectors, where precision is paramount and human lives are directly impacted, these ...

A combination regimen for kidney cancer treatment based on MSD's Welireg has failed a phase 3 trial, denting the company's ...

After years of constrained capital markets, biotech companies are operating in an environment where even late-stage ...

Preeclampsia is a serious pregnancy disorder, affecting nearly 10 millionwomen globally each year, and can strike without ...

Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...

Jazz Pharma's Ziihera and Eli Lilly's Jaypirca, respectively – have been recommended by reimbursement agency NICE for NHS use ...

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Italian drive to increase diagnosis rates in children with severe genetic disorders is achieving transformative results. The ...

Faruk Uzman is Vice President Europe, Middle East, Africa at Boston Scientific. He joined Boston Scientific in 2018 and ...